LLY vs NVS stock comparison
ELI LILLY & Co vs. Novartis · data as of November 13, 2026
ELI LILLY & Co (LLY) has a market value of about $1.36T, Novartis (NVS) about $306.3B. Over their latest twelve months ELI LILLY & Co had revenue of $86.5B and Novartis $57.4B.
On our five checks ELI LILLY & Co scores higher: 3.4 out of 5 (good) against 2.0 (weak).
By area, the stronger company is ELI LILLY & Co on future growth; ELI LILLY & Co on track record; ELI LILLY & Co on shareholder returns.
Novartis is cheaper on earnings (P/E 30.7 vs. 46.9), while ELI LILLY & Co grew revenue faster over five years (21.6% vs. 2.3% a year).
ELI LILLY & Co leads on 14 of the compared lines and Novartis on 9.
Side by side
| LLY | NVS | |
|---|---|---|
| Size and price | ||
| Market cap | $1.36T | $306.3B |
| Share price | $1,443.50 | $160.50 |
| Score | ||
| Overall score (of 5) | 3.4 | 2.0 |
| Value | 0 | 0 |
| Future growth | 5 | 0 |
| Track record | 5 | 4 |
| Financial health | 3 | 3 |
| Shareholder returns | 4 | 3 |
| Valuation | ||
| P/E (TTM) | 46.9 | 30.7 |
| Forward P/E | 30.4 | 17.0 |
| Price / free cash flow | 69.1 | 21.9 |
| Price / sales | 15.7 | 5.3 |
| EV / EBITDA | 37.1 | 14.4 |
| PEG | 1.70 | 2.02 |
| DCF value vs. price | −37% | −9% |
| Business | ||
| Revenue | $86.5B | $57.4B |
| Net income | $27.6B | $10.0B |
| Free cash flow | $19.7B | $14.0B |
| Net margin | 31.9% | 17.5% |
| Gross margin (5-yr avg.) | 78.9% | 76.4% |
| ROIC (5-yr avg.) | 22.9% | 14.1% |
| Growth | ||
| Revenue growth (1 yr) | 44.7% | 8.4% |
| Revenue growth (5 yrs, per year) | 21.6% | 2.3% |
| EPS growth (5 yrs, per year) | 27.6% | 15.2% |
| Balance sheet and payouts | ||
| Net cash (cash minus debt) | -$44.6B | -$39.3B |
| Dividend yield | 0.48% | 2.95% |
| Shareholder yield | 0.8% | 6.0% |
| Analysts | ||
| Upside to average target | +1% | −2% |
| Consensus rating | Buy | Hold |
Highlighted = the better figure on that line. Revenue, net income and free cash flow: LLY TTM to September 30, 2026, NVS TTM to September 30, 2026. Not investment advice.
Frequently asked questions
Which is the better stock, ELI LILLY & Co or Novartis?
We do not give buy or sell advice. On our five checks (value, growth, track record, financial health and shareholder returns) ELI LILLY & Co scores 3.4 out of 5 and Novartis 2.0; the table shows where each one is stronger.
Is ELI LILLY & Co cheaper than Novartis?
On trailing earnings, Novartis trades at a P/E of 30.7 and ELI LILLY & Co at 46.9, so Novartis is cheaper by this measure. A lower P/E can also reflect slower expected growth.
Which grows faster, ELI LILLY & Co or Novartis?
Over five years ELI LILLY & Co grew revenue about 21.6% a year and Novartis about 2.3% a year.
Which pays a higher dividend?
ELI LILLY & Co yields 0.48% and Novartis 2.95%.
Full ELI LILLY & Co analysis → Full Novartis analysis →
More comparisons
Generated from SEC filings, analyst consensus estimates and market prices, rebuilt every day. Educational information, not investment advice.